1. Home
  2. PHAR vs AOD Comparison

PHAR vs AOD Comparison

Compare PHAR & AOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$15.46

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo abrdn Total Dynamic Dividend Fund of Beneficial Interest

AOD

abrdn Total Dynamic Dividend Fund of Beneficial Interest

HOLD

Current Price

$9.73

Market Cap

998.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
AOD
Founded
1988
N/A
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
998.4M
IPO Year
2020
2006

Fundamental Metrics

Financial Performance
Metric
PHAR
AOD
Price
$15.46
$9.73
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$39.00
N/A
AVG Volume (30 Days)
20.2K
675.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.04
N/A
Revenue Next Year
$2.70
N/A
P/E Ratio
$3,041.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.50
$7.65
52 Week High
$21.34
$10.77

Technical Indicators

Market Signals
Indicator
PHAR
AOD
Relative Strength Index (RSI) 43.95 40.94
Support Level $12.98 $9.57
Resistance Level $17.29 $10.10
Average True Range (ATR) 0.66 0.18
MACD -0.01 -0.05
Stochastic Oscillator 29.43 28.03

Price Performance

Historical Comparison
PHAR
AOD

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest

Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.

Share on Social Networks: